Unternehmensprofil von Watson Pharmaceuticals - 500 Beiträge pro Seite
eröffnet am 24.08.00 19:41:02 von
neuester Beitrag 26.09.00 00:39:31 von
neuester Beitrag 26.09.00 00:39:31 von
Beiträge: 23
ID: 223.371
ID: 223.371
Aufrufe heute: 0
Gesamt: 841
Gesamt: 841
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 6608 | |
| vor 56 Minuten | 5261 | |
| vor 22 Minuten | 4419 | |
| heute 18:26 | 4052 | |
| vor 48 Minuten | 2862 | |
| vor 1 Stunde | 2082 | |
| heute 14:53 | 1965 | |
| vor 23 Minuten | 1604 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 18.185,97 | +1,43 | 236 | |||
| 2. | 3. | 0,1855 | -1,85 | 97 | |||
| 3. | 2. | 1,1000 | -20,29 | 96 | |||
| 4. | 5. | 9,3650 | +1,30 | 63 | |||
| 5. | 4. | 166,76 | -2,01 | 57 | |||
| 6. | Neu! | 0,4250 | -1,16 | 40 | |||
| 7. | Neu! | 4,7940 | +6,89 | 34 | |||
| 8. | Neu! | 11,905 | +14,97 | 32 |
Feedback
...kann jemand mir hier ein solches reinstellen, bitte auf deutsch??
Danke
Mike
Danke
Mike
Dann eben nicht, aber ich hab noch einiges gefunden:
Press Release
SOURCE: Schein Pharmaceutical, Inc.
Schein Pharmaceutical Announces Merger with Watson Subsidiary Approved By Schein Shareholders
FLORHAM PARK, N.J., Aug. 28 /PRNewswire/ -- Schein Pharmaceutical, Inc. (NYSE: SHP - news) announced today that the merger with a subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI - news), was approved by the stockholders of Schein at the special meeting held on August 28, 2000.
Schein Pharmaceutical, Inc., headquartered in Florham Park, NJ, is a pharmaceutical company that has a diverse portfolio of both brand and generic products. Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products.
SOURCE: Schein Pharmaceutical, Inc.
Press Release
SOURCE: Schein Pharmaceutical, Inc.
Schein Pharmaceutical Announces Merger with Watson Subsidiary Approved By Schein Shareholders
FLORHAM PARK, N.J., Aug. 28 /PRNewswire/ -- Schein Pharmaceutical, Inc. (NYSE: SHP - news) announced today that the merger with a subsidiary of Watson Pharmaceuticals, Inc. (NYSE: WPI - news), was approved by the stockholders of Schein at the special meeting held on August 28, 2000.
Schein Pharmaceutical, Inc., headquartered in Florham Park, NJ, is a pharmaceutical company that has a diverse portfolio of both brand and generic products. Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products.
SOURCE: Schein Pharmaceutical, Inc.
Und das hier von heute:
Press Release
SOURCE: Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals Completes Acquisition of Schein Pharmaceutical, Inc.
CORONA, Calif., Aug. 28 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI - news) announced today the completion of its acquisition of Schein Pharmaceutical, Inc. (NYSE: SHP - news). Under the terms of its merger agreement with Schein, Watson acquired all of the outstanding stock of Schein through a two-step transaction comprised of a cash tender offer followed by a taxable stock merger. The cash tender offer was at $19.50 per share of Schein common stock while, pursuant to the merger, each Schein share not tendered was converted into the right to receive 0.42187 of a share of Watson common stock. In exchange for the remaining outstanding Schein shares, Watson will issue, pursuant to the merger, approximately 5.3 million common shares of Watson stock. As a result of the merger, Schein is now a wholly owned subsidiary of Watson.
This press release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Watson`s or Schein`s estimated or anticipated future results, product development efforts or performance or other non-historical facts are forward-looking and reflect each company`s current perspective of existing trends and information. Such forward-looking statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, risks associated with the integration of the Watson and Schein businesses after consummation of the acquisition, and such other risks and uncertainties detailed in each company`s filings with the Securities and Exchange Commission.
This release and past press releases of Watson are available at Watson`s web site at http://www.watsonpharm.com . In addition, Watson`s press releases are available through PR Newswire`s Company News On-Call fax service at 800-758-5804, extension 112856, and at http://www.prnewswire.com .
SOURCE: Watson Pharmaceuticals, Inc.
Press Release
SOURCE: Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals Completes Acquisition of Schein Pharmaceutical, Inc.
CORONA, Calif., Aug. 28 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI - news) announced today the completion of its acquisition of Schein Pharmaceutical, Inc. (NYSE: SHP - news). Under the terms of its merger agreement with Schein, Watson acquired all of the outstanding stock of Schein through a two-step transaction comprised of a cash tender offer followed by a taxable stock merger. The cash tender offer was at $19.50 per share of Schein common stock while, pursuant to the merger, each Schein share not tendered was converted into the right to receive 0.42187 of a share of Watson common stock. In exchange for the remaining outstanding Schein shares, Watson will issue, pursuant to the merger, approximately 5.3 million common shares of Watson stock. As a result of the merger, Schein is now a wholly owned subsidiary of Watson.
This press release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Watson`s or Schein`s estimated or anticipated future results, product development efforts or performance or other non-historical facts are forward-looking and reflect each company`s current perspective of existing trends and information. Such forward-looking statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, risks associated with the integration of the Watson and Schein businesses after consummation of the acquisition, and such other risks and uncertainties detailed in each company`s filings with the Securities and Exchange Commission.
This release and past press releases of Watson are available at Watson`s web site at http://www.watsonpharm.com . In addition, Watson`s press releases are available through PR Newswire`s Company News On-Call fax service at 800-758-5804, extension 112856, and at http://www.prnewswire.com .
SOURCE: Watson Pharmaceuticals, Inc.
Tschuldigung, der vorige war von gestern, aber der hier ist von heute:
Press Release
SOURCE: Watson Pharmaceuticals, Inc.
Watson Names Donald Britt as Senior Vice President of Corporate Quality Assurance
CORONA, Calif., Aug. 29 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI - news) today announced the appointment of Donald Britt as Senior Vice President of Corporate Quality Assurance. In this role, he will report directly to Allen Chao, Ph.D., Chairman and Chief Executive Officer.
``We are delighted Don has joined the Watson team in this critically important role,`` began Dr. Chao. ``As a corporate officer, Don will oversee all quality programs for Watson, ensuring a coordinated and integrated approach to quality at all of Watson`s facilities. Don`s reputation and achievements throughout his 30-year tenure in the pharmaceutical environment will complement our continuing progress in implementing our quality improvement programs,`` Chao added.
Don joins Watson following his position as Senior Vice President of Quality for Schein Pharmaceutical. Prior to Schein, Don had been Senior Vice President of QA/QC and Compliance for Centocor; Vice President of Worldwide Quality for Aventis; Senior Vice President of Worldwide Quality for Rhone-Poulenc Rorer; Vice President of Quality with Fisons, and had many assignments in QA/QC during his early career at Glaxo.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products. Watson pursues a strategy of generating revenue through established proprietary and off-patent businesses, capitalizing on its proven ability to support the development and commercialization of a broad range of off-patent and specialty pharmaceutical products.
This and past press releases of Watson Pharmaceuticals, Inc. are available at Watson`s web site at www.watsonpharm.com. In addition, press releases are available through PR Newswire`s Company On-Call fax service at 800-758-5804, extension 112856, and at www.prnewswire.com.
SOURCE: Watson Pharmaceuticals, Inc.
Press Release
SOURCE: Watson Pharmaceuticals, Inc.
Watson Names Donald Britt as Senior Vice President of Corporate Quality Assurance
CORONA, Calif., Aug. 29 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI - news) today announced the appointment of Donald Britt as Senior Vice President of Corporate Quality Assurance. In this role, he will report directly to Allen Chao, Ph.D., Chairman and Chief Executive Officer.
``We are delighted Don has joined the Watson team in this critically important role,`` began Dr. Chao. ``As a corporate officer, Don will oversee all quality programs for Watson, ensuring a coordinated and integrated approach to quality at all of Watson`s facilities. Don`s reputation and achievements throughout his 30-year tenure in the pharmaceutical environment will complement our continuing progress in implementing our quality improvement programs,`` Chao added.
Don joins Watson following his position as Senior Vice President of Quality for Schein Pharmaceutical. Prior to Schein, Don had been Senior Vice President of QA/QC and Compliance for Centocor; Vice President of Worldwide Quality for Aventis; Senior Vice President of Worldwide Quality for Rhone-Poulenc Rorer; Vice President of Quality with Fisons, and had many assignments in QA/QC during his early career at Glaxo.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products. Watson pursues a strategy of generating revenue through established proprietary and off-patent businesses, capitalizing on its proven ability to support the development and commercialization of a broad range of off-patent and specialty pharmaceutical products.
This and past press releases of Watson Pharmaceuticals, Inc. are available at Watson`s web site at www.watsonpharm.com. In addition, press releases are available through PR Newswire`s Company On-Call fax service at 800-758-5804, extension 112856, and at www.prnewswire.com.
SOURCE: Watson Pharmaceuticals, Inc.
Jetzt brauch ich nur noch jemanden, der besseres Geschäfts-Englisch als ich kann und mir verrät, was diese Beiträge wohl bedeuten könnten.
Danke,
Mike
Danke,
Mike
Trading Spotlight
Hier noch ein Unternehmensprofil, leider auch nur in englisch:
Profile:
Watson Pharmaceuticals, Inc. is a pharmaceutical company primarily engaged in the development, production, marketing and distribution of both branded and off-patent pharmaceutical products. Our products include therapeutic and preventive agents generally sold by prescription or over-the-counter for the treatment of human diseases and disorders. For full prescribing information for any Watson product, please contact the company at (800) 272-5525.
Watson was incorporated in January 1985, and commenced operations as a manufacturer and marketer of off-patent pharmaceuticals. We have grown, through internal product development and synergistic acquisitions of products and businesses, into a diversified specialty pharmaceutical company that currently markets over 100 branded and off-patent products. We are also engaged in the development of advanced drug delivery systems primarily designed to enhance the therapeutic benefits of pharmaceutical products, both to expand our own product line and under collaborative agreements with other parties.
Mike
Profile:
Watson Pharmaceuticals, Inc. is a pharmaceutical company primarily engaged in the development, production, marketing and distribution of both branded and off-patent pharmaceutical products. Our products include therapeutic and preventive agents generally sold by prescription or over-the-counter for the treatment of human diseases and disorders. For full prescribing information for any Watson product, please contact the company at (800) 272-5525.
Watson was incorporated in January 1985, and commenced operations as a manufacturer and marketer of off-patent pharmaceuticals. We have grown, through internal product development and synergistic acquisitions of products and businesses, into a diversified specialty pharmaceutical company that currently markets over 100 branded and off-patent products. We are also engaged in the development of advanced drug delivery systems primarily designed to enhance the therapeutic benefits of pharmaceutical products, both to expand our own product line and under collaborative agreements with other parties.
Mike
Hallo Mike
Watson ist ein Gerika-Hersteller. Fuer dies Firmen interessiet sich hier keiner. Deshalb kein Feedback.
Hab leider kein besonderes Uebersetzungspr. und mein Englisch ist auch nicht mehr das beste hoffe es reicht dir.
Pressemitteilungsquelle: Watson Pharmaka, Inc. Watson nennt Donald Britt so älteren Vizepräsidenten korporativer Qualitätssicherungskorona, Calif Aug 29 /PRNewswire/-Watson Pharmaka, Inc. (NYSE): (WPI -- Nachrichten) heute kündigte den Termin des Donald Britt so älteren Vizepräsidenten korporativer Qualitätssicherung an. In dieser Rolle berichtet er direkt Allen Chao, Ph.D., Vorsitzendem und Regierungschefleiter.
``Wir sind erfreut anziehen hat das Watson Team in diesem zusammengefügt, als das kritisch wichtiger Rolle, `` begann, Dr. Chao. ``Als eine korporative Leiter ziehen Sie an überblickt alle Qualitätsprogramme für Watson, einen koordinierten und integrierten Ansatz zu Qualität an allen von Watson ` S Einrichtungen sicherstellend. Ziehen Sie ` S Ruf an, und Ergebnisse überall in seiner 30jährigen Anstellung in der pharmazeutischen Umgebung ergänzen unseren hinzugefügten kontinuierlichen Fortschritt dabei, unseren Qualitätsverbesserungsprogramme, `` Chao durchzuführen.
Ziehen Sie Verknüpfungen an Watson seiner Position als älterer Vizepräsident der Qualität für Schein Pharmakum folgen. Vor Schein ziehen Sie an, war älterer Vizepräsident von QA/QC und Einhaltung für Centocor gewesen; Vizepräsident weltweiter Qualität für Aventis; Älterer Vizepräsident weltweiter Qualität für Rhone Poulenc Rorer; Vizepräsident der Qualität mit Fisons, und hatte viele Übertragungen in QA/QC während seiner frühen Karriere an Glaxo.
Watson Pharmaka, Inc., etabliert in Korona, CA, ist mit der Entwicklung, der Herstellung und dem Verkauf beschäftigt von Eigentums- und läßt aus pharmazeutische Produkte patentieren. Watson geht einer Strategie nach, Erlös zu generieren, durch stellte fest Eigentums- und läßt aus Geschäfte, Kapitalisieren auf seiner bewährten Fähigkeit patentieren, die Entwicklung und Kommerzialisierung zu unterstützen, von einem breiten Spektrum von von-Patent und Spezialitätspharmakum Produkte.
Dies und letzte Pressemitteilungen des Watson Pharmaka, Inc. stehen an Watson ` S Netzstandort an Www.watsonpharm.com zur Verfügung. Außerdem stehen Pressemitteilungen durch PR Newswire ` S zur Verfügung Gesellschaft Bereitschaftstelefaxdienstleistung an 800-758-5804, Erweiterung 112856 und an Www.prnewswire.com.
Quelle: Watson Pharmaka, Inc.
Keine weltbewegende Nachricht.
Watson halte ich fuer durchaus interessant.
Wenn du dir den 3 JAhreschart ansiehts wirst du feststellen das die wieder alte höhen erklimmen. Vergleichbare Firmen sind Andrx IVAX TEVa und Biovail. Der Kurs von Watson ist gegenueber den anderen Firmen etwas zurueckgebliieben. Haegt vermutlich(ist aber nur Sekulation) mit dem Einbruch zusammen. Konnte leider bislang nicht herausfinden woran das damals gelegen hat.
Mal sehen was sich in den naechsten Wochen da tut. Grundsätzlich eine sehr solide Sache.
gruss
gigalooser
Watson ist ein Gerika-Hersteller. Fuer dies Firmen interessiet sich hier keiner. Deshalb kein Feedback.
Hab leider kein besonderes Uebersetzungspr. und mein Englisch ist auch nicht mehr das beste hoffe es reicht dir.
Pressemitteilungsquelle: Watson Pharmaka, Inc. Watson nennt Donald Britt so älteren Vizepräsidenten korporativer Qualitätssicherungskorona, Calif Aug 29 /PRNewswire/-Watson Pharmaka, Inc. (NYSE): (WPI -- Nachrichten) heute kündigte den Termin des Donald Britt so älteren Vizepräsidenten korporativer Qualitätssicherung an. In dieser Rolle berichtet er direkt Allen Chao, Ph.D., Vorsitzendem und Regierungschefleiter.
``Wir sind erfreut anziehen hat das Watson Team in diesem zusammengefügt, als das kritisch wichtiger Rolle, `` begann, Dr. Chao. ``Als eine korporative Leiter ziehen Sie an überblickt alle Qualitätsprogramme für Watson, einen koordinierten und integrierten Ansatz zu Qualität an allen von Watson ` S Einrichtungen sicherstellend. Ziehen Sie ` S Ruf an, und Ergebnisse überall in seiner 30jährigen Anstellung in der pharmazeutischen Umgebung ergänzen unseren hinzugefügten kontinuierlichen Fortschritt dabei, unseren Qualitätsverbesserungsprogramme, `` Chao durchzuführen.
Ziehen Sie Verknüpfungen an Watson seiner Position als älterer Vizepräsident der Qualität für Schein Pharmakum folgen. Vor Schein ziehen Sie an, war älterer Vizepräsident von QA/QC und Einhaltung für Centocor gewesen; Vizepräsident weltweiter Qualität für Aventis; Älterer Vizepräsident weltweiter Qualität für Rhone Poulenc Rorer; Vizepräsident der Qualität mit Fisons, und hatte viele Übertragungen in QA/QC während seiner frühen Karriere an Glaxo.
Watson Pharmaka, Inc., etabliert in Korona, CA, ist mit der Entwicklung, der Herstellung und dem Verkauf beschäftigt von Eigentums- und läßt aus pharmazeutische Produkte patentieren. Watson geht einer Strategie nach, Erlös zu generieren, durch stellte fest Eigentums- und läßt aus Geschäfte, Kapitalisieren auf seiner bewährten Fähigkeit patentieren, die Entwicklung und Kommerzialisierung zu unterstützen, von einem breiten Spektrum von von-Patent und Spezialitätspharmakum Produkte.
Dies und letzte Pressemitteilungen des Watson Pharmaka, Inc. stehen an Watson ` S Netzstandort an Www.watsonpharm.com zur Verfügung. Außerdem stehen Pressemitteilungen durch PR Newswire ` S zur Verfügung Gesellschaft Bereitschaftstelefaxdienstleistung an 800-758-5804, Erweiterung 112856 und an Www.prnewswire.com.
Quelle: Watson Pharmaka, Inc.
Keine weltbewegende Nachricht.
Watson halte ich fuer durchaus interessant.
Wenn du dir den 3 JAhreschart ansiehts wirst du feststellen das die wieder alte höhen erklimmen. Vergleichbare Firmen sind Andrx IVAX TEVa und Biovail. Der Kurs von Watson ist gegenueber den anderen Firmen etwas zurueckgebliieben. Haegt vermutlich(ist aber nur Sekulation) mit dem Einbruch zusammen. Konnte leider bislang nicht herausfinden woran das damals gelegen hat.
Mal sehen was sich in den naechsten Wochen da tut. Grundsätzlich eine sehr solide Sache.
gruss
gigalooser
mitie, finde es gut, dass du eine aktie wie watson interessant findest, denn selber denken macht reich. 
wenn du eine allgemeine diskussion über generika interessant findest, dann schau doch einfach im thread "ein ganzes segment von einem hoch zum anderen- und keinen interessiert´s" nach, bringe evtl. eigenes wissen und meinung ein.
im übrigen bin ich auch hier gigaloosers meinung, dass es sich in diesem bereich um eine sehr zukunftsträchtige branche handelt.
andere werte aber immer mit beobachten, da einige den trend der anderen vorzugeben scheinen.
gruß
wenn du eine allgemeine diskussion über generika interessant findest, dann schau doch einfach im thread "ein ganzes segment von einem hoch zum anderen- und keinen interessiert´s" nach, bringe evtl. eigenes wissen und meinung ein.
im übrigen bin ich auch hier gigaloosers meinung, dass es sich in diesem bereich um eine sehr zukunftsträchtige branche handelt.
andere werte aber immer mit beobachten, da einige den trend der anderen vorzugeben scheinen.
gruß
Wurde Watson nicht von der tecis AG übernommen?
Ouwa?
Ouwa?
Da liegst du leider total falsch! Dümmer gehts ja gar nicht, du Gurke!
@epicuraul: Ich werd mir den Thread mal ansehen,
Danke,
Mike
@epicuraul: Ich werd mir den Thread mal ansehen,
Danke,
Mike
Watson entwickelt sich recht nett, eben Generika-like!
Mike
Mike
Los gehts:
Watson to Pursue Strategic Alternatives for Schein`s Two Sterile Injectable ...
CORONA, Calif., Sep 5, 2000 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals,Inc. (NYSE: WPI) announced today its intent to seek strategic alternatives, including the possible divestiture, for its two sterile injectable manufacturing facilities in Phoenix, Arizona and Cherry Hill, New Jersey. The Phoenix and Cherry Hill facilities were recently acquired in connection with Watson`s acquisition of Schein Pharmaceutical, Inc., which was completed on August 28, 2000.
Watson further confirmed that it intends to continue its sales and marketing programs for INFeD(R) and Ferrlecit(R). Although INFeD(R) is currently manufactured at the Phoenix facility, Watson commented that it would consider a contract manufacturing arrangement for INFeD(R) as part of its plans for the Phoenix facility. Ferrlecit(R) is already being produced for Watson by a contract manufacturer, Aventis.
"As we continue to expand our business operations, we remain focused on our strategic initiatives for growth," began Watson`s Chairman and Chief Executive Officer Allen Chao, Ph.D. "We believe this decision will allow us to concentrate our energies, efforts and resources on our current operations, maximizing the value-creation capabilities of our strong core businesses and our proven expertise in manufacturing solid dosage form products," he added.
To assist in the evaluation of possible alternatives for the Phoenix and Cherry Hill facilities, Watson has retained the investment banking firm of CIBC World Markets to handle all inquiries and related matters.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products. Watson pursues a strategy of generating revenue through established proprietary and off-patent businesses, capitalizing on its proven ability to support the development and commercialization of a broad range of proprietary and off-patent pharmaceutical products.
This press release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Watson`s estimated or anticipated future results, product development efforts or performance or other non-historical facts are forward-looking and reflect Watson`s current perspective of existing trends and information. Such forward-looking statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, risks associated with the integration by Watson of Schein`s operations and business, uncertainties related to the terms or consummation of any strategic alternatives to be considered concerning the Phoenix or Cherry Hill facilities, and such other risks and uncertainties detailed in Watson`s filings with the Securities and Exchange Commission, including without limitation Watson`s Annual Report and Form 10-K for the year ended December 31, 1999, Form 10-Q for the quarter ended June 30, 2000 and Registration Statement on Form S-4 filed on July 14, 2000, as amended.
This release and past press releases of Watson are available at Watson`s web site at http://www.watsonpharm.com . In addition, Watson`s press releases are available through PR Newswire`s Company News On-Call fax service at 800-758-5804, extension 112856, and at http://www.prnewswire.com .
SOURCE Watson Pharmaceuticals, Inc.
CONTACT: Sara Swee, Director, Corporate Communications of Watson Pharmaceuticals, Inc., 909-270-1400; or Investor/Media Relations, Jim Byers or Danielle Scheg of Morgen-Walke Associates, Inc., 415-296-7383, for Watson Pharmaceuticals, Inc. /Company News On-Call: http://www.prnewswire.com/comp/112856.html or fax, 800-758-5804, ext. 112856
URL: http://www.watsonpharm.com http://www.prnewswire.com
Alles klar?
Euer Mike
Watson to Pursue Strategic Alternatives for Schein`s Two Sterile Injectable ...
CORONA, Calif., Sep 5, 2000 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals,Inc. (NYSE: WPI) announced today its intent to seek strategic alternatives, including the possible divestiture, for its two sterile injectable manufacturing facilities in Phoenix, Arizona and Cherry Hill, New Jersey. The Phoenix and Cherry Hill facilities were recently acquired in connection with Watson`s acquisition of Schein Pharmaceutical, Inc., which was completed on August 28, 2000.
Watson further confirmed that it intends to continue its sales and marketing programs for INFeD(R) and Ferrlecit(R). Although INFeD(R) is currently manufactured at the Phoenix facility, Watson commented that it would consider a contract manufacturing arrangement for INFeD(R) as part of its plans for the Phoenix facility. Ferrlecit(R) is already being produced for Watson by a contract manufacturer, Aventis.
"As we continue to expand our business operations, we remain focused on our strategic initiatives for growth," began Watson`s Chairman and Chief Executive Officer Allen Chao, Ph.D. "We believe this decision will allow us to concentrate our energies, efforts and resources on our current operations, maximizing the value-creation capabilities of our strong core businesses and our proven expertise in manufacturing solid dosage form products," he added.
To assist in the evaluation of possible alternatives for the Phoenix and Cherry Hill facilities, Watson has retained the investment banking firm of CIBC World Markets to handle all inquiries and related matters.
Watson Pharmaceuticals, Inc., headquartered in Corona, CA, is engaged in the development, manufacture and sale of proprietary and off-patent pharmaceutical products. Watson pursues a strategy of generating revenue through established proprietary and off-patent businesses, capitalizing on its proven ability to support the development and commercialization of a broad range of proprietary and off-patent pharmaceutical products.
This press release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statements that refer to Watson`s estimated or anticipated future results, product development efforts or performance or other non-historical facts are forward-looking and reflect Watson`s current perspective of existing trends and information. Such forward-looking statements involve risks and uncertainties that cannot be predicted or quantified and, consequently, actual results may differ materially from those expressed or implied by such statements. Such risks and uncertainties include, among others, risks associated with the integration by Watson of Schein`s operations and business, uncertainties related to the terms or consummation of any strategic alternatives to be considered concerning the Phoenix or Cherry Hill facilities, and such other risks and uncertainties detailed in Watson`s filings with the Securities and Exchange Commission, including without limitation Watson`s Annual Report and Form 10-K for the year ended December 31, 1999, Form 10-Q for the quarter ended June 30, 2000 and Registration Statement on Form S-4 filed on July 14, 2000, as amended.
This release and past press releases of Watson are available at Watson`s web site at http://www.watsonpharm.com . In addition, Watson`s press releases are available through PR Newswire`s Company News On-Call fax service at 800-758-5804, extension 112856, and at http://www.prnewswire.com .
SOURCE Watson Pharmaceuticals, Inc.
CONTACT: Sara Swee, Director, Corporate Communications of Watson Pharmaceuticals, Inc., 909-270-1400; or Investor/Media Relations, Jim Byers or Danielle Scheg of Morgen-Walke Associates, Inc., 415-296-7383, for Watson Pharmaceuticals, Inc. /Company News On-Call: http://www.prnewswire.com/comp/112856.html or fax, 800-758-5804, ext. 112856
URL: http://www.watsonpharm.com http://www.prnewswire.com
Alles klar?
Euer Mike
SOURCE: Massachusetts General Hospital
New England Journal of Medicine Study Reports that Testosterone Skin Patch Improves Sexual Functioning in Surgically Menopausal Women
BOSTON, Sept. 6 /PRNewswire/ -- A multi-institutional research group has found that use of an experimental testosterone skin patch can relieve impaired sexual functioning in surgically menopausal women -- that is, women who have had their ovaries removed before natural menopause. The report in the Sept. 7 New England Journal of Medicine comes from a team led by researchers from the Massachusetts General Hospital (MGH) and Watson Laboratories, Inc.-Utah, a division of Watson Pharmaceuticals (NYSE: WPI - news), the developers of the patch.
New England Journal of Medicine Study Reports that Testosterone Skin Patch Improves Sexual Functioning in Surgically Menopausal Women
BOSTON, Sept. 6 /PRNewswire/ -- A multi-institutional research group has found that use of an experimental testosterone skin patch can relieve impaired sexual functioning in surgically menopausal women -- that is, women who have had their ovaries removed before natural menopause. The report in the Sept. 7 New England Journal of Medicine comes from a team led by researchers from the Massachusetts General Hospital (MGH) and Watson Laboratories, Inc.-Utah, a division of Watson Pharmaceuticals (NYSE: WPI - news), the developers of the patch.
BOSTON (Reuters) - Testosterone patches can help restore the sex drive of women whose ovaries have been removed, researchers report in Thursday`s New England Journal of Medicine.
Testosterone is best known as a male hormone, but it is also produced in small amounts in a woman`s adrenal glands and the ovaries, which also make the ``female`` hormone estrogen.
When women have both their ovaries removed, doctors usually offer estrogen treatment to prevent hot flashes, osteoporosis and heart disease. But doctors do not try to replace the lost testosterone, which women need to maintain energy levels, keep muscle mass and retain a strong libido.
The study, funded by Procter and Gamble Pharmaceuticals (NYSE:PG - news) and conducted by Watson Laboratories (NYSE:WPI - news) and Massachusetts General Hospital (MGH), was part of a Phase II clinical trial for the patch. Phase II trials determine if a treatment actually works as expected.
(Ende der Mitteilung)
Also: Watson hat überall ein wenig die Finger drin und ist glücklicherweise auch immer erfolgreich. Der Artikel ist jedoch sicherlich nicht der Auslöser für die hervorragende Performance der letzten Tage und besonders heute.
Mike
Testosterone is best known as a male hormone, but it is also produced in small amounts in a woman`s adrenal glands and the ovaries, which also make the ``female`` hormone estrogen.
When women have both their ovaries removed, doctors usually offer estrogen treatment to prevent hot flashes, osteoporosis and heart disease. But doctors do not try to replace the lost testosterone, which women need to maintain energy levels, keep muscle mass and retain a strong libido.
The study, funded by Procter and Gamble Pharmaceuticals (NYSE:PG - news) and conducted by Watson Laboratories (NYSE:WPI - news) and Massachusetts General Hospital (MGH), was part of a Phase II clinical trial for the patch. Phase II trials determine if a treatment actually works as expected.
(Ende der Mitteilung)
Also: Watson hat überall ein wenig die Finger drin und ist glücklicherweise auch immer erfolgreich. Der Artikel ist jedoch sicherlich nicht der Auslöser für die hervorragende Performance der letzten Tage und besonders heute.
Mike
@mitie, hier mal ein vergleich von watson zum gesamten sektor:
(sollte eigentlich die unterbewertung klarstellen)
RATIO COMPARISON
Valuation Ratios Company Industry Sector S&P 500
P/E Ratio (TTM) 17.78 47.04 46.95 36.56
Beta 0.34 0.68 0.77 1.00
Price to Sales (TTM) 8.51 26.62 11.41 8.84
Price to Book (MRQ) 4.53 14.83 12.97 10.06
Price to Tangible Book (MRQ) 7.75 16.72 17.40 14.09
Price to Cash Flow (TTM) 15.63 36.11 35.82 27.47
Price to Free Cash Flow (TTM) NM 56.86 51.93 41.69
% Owned Institutions 65.01 33.92 47.07 56.82
Growth Rates(%) Company Industry Sector S&P 500
Sales (MRQ) vs Qtr. 1 Yr. Ago 11.56 34.87 16.62 24.20
Sales (TTM) vs TTM 1 Yr. Ago 13.84 25.48 16.31 23.14
Sales - 5 Yr. Growth Rate 39.79 36.11 20.90 21.43
EPS (MRQ) vs Qtr. 1 Yr. Ago 104.67 34.06 12.44 23.95
EPS (TTM) vs TTM 1 Yr. Ago 159.04 35.95 31.74 26.16
EPS - 5 Yr. Growth Rate 32.79 31.12 18.12 22.76
Capital Spending - 5 Yr. Growth Rate 43.91 21.88 16.20 5.80
Financial Strength Company Industry Sector S&P 500
Quick Ratio (MRQ) 4.46 8.75 3.14 1.30
Current Ratio (MRQ) 6.14 9.47 3.78 1.79
LT Debt to Equity (MRQ) 0.11 0.45 0.31 0.55
Total Debt to Equity (MRQ) 0.11 0.49 0.44 0.84
Interest Coverage (TTM) 24.23 -2.16 10.14 9.86
Profitability Ratios (%) Company Industry Sector S&P 500
Gross Margin (TTM) 64.92 64.17 68.53 50.29
Gross Margin - 5 Yr. Avg. 60.33 66.74 66.37 48.37
EBITD Margin (TTM) 40.50 7.77 23.01 23.09
EBITD - 5 Yr. Avg. 32.92 -4.80 20.38 21.25
Operating Margin (TTM) 35.93 0.23 18.12 17.94
Operating Margin - 5 Yr. Avg. 30.85 -13.38 12.86 16.94
Pre-Tax Margin (TTM) 75.21 2.70 19.01 17.88
Pre-Tax Margin - 5 Yr. Avg. 39.23 -11.80 13.22 16.75
Net Profit Margin (TTM) 47.92 -0.47 12.58 12.99
Net Profit Margin - 5 Yr. Avg. 25.53 -13.37 8.06 10.25
Management Effectiveness (%) Company Industry Sector S&P 500
Return On Assets (TTM) 22.07 -8.08 9.14 10.53
Return On Assets - 5 Yr. Avg. 15.67 -12.81 7.03 9.05
Return On Investment (TTM) 23.82 -7.58 13.95 13.97
Return On Investment - 5 Yr. Avg. 17.25 -10.06 12.73 14.22
Return On Equity (TTM) 29.89 -1.68 23.40 22.32
Return On Equity - 5 Yr. Avg. 19.39 -9.97 20.53 21.92
Efficiency Company Industry Sector S&P 500
Revenue/Employee (TTM) 374,003 346,527 340,275 615,548
Net Income/Employee (TTM) 179,213 74,729 65,197 103,543
Receivable Turnover (TTM) 5.10 8.79 7.00 8.62
Inventory Turnover (TTM) 2.15 5.04 3.83 9.58
Asset Turnover (TTM) 0.46 0.61 0.86 0.99
gruß
(sollte eigentlich die unterbewertung klarstellen)
RATIO COMPARISON
Valuation Ratios Company Industry Sector S&P 500
P/E Ratio (TTM) 17.78 47.04 46.95 36.56
Beta 0.34 0.68 0.77 1.00
Price to Sales (TTM) 8.51 26.62 11.41 8.84
Price to Book (MRQ) 4.53 14.83 12.97 10.06
Price to Tangible Book (MRQ) 7.75 16.72 17.40 14.09
Price to Cash Flow (TTM) 15.63 36.11 35.82 27.47
Price to Free Cash Flow (TTM) NM 56.86 51.93 41.69
% Owned Institutions 65.01 33.92 47.07 56.82
Growth Rates(%) Company Industry Sector S&P 500
Sales (MRQ) vs Qtr. 1 Yr. Ago 11.56 34.87 16.62 24.20
Sales (TTM) vs TTM 1 Yr. Ago 13.84 25.48 16.31 23.14
Sales - 5 Yr. Growth Rate 39.79 36.11 20.90 21.43
EPS (MRQ) vs Qtr. 1 Yr. Ago 104.67 34.06 12.44 23.95
EPS (TTM) vs TTM 1 Yr. Ago 159.04 35.95 31.74 26.16
EPS - 5 Yr. Growth Rate 32.79 31.12 18.12 22.76
Capital Spending - 5 Yr. Growth Rate 43.91 21.88 16.20 5.80
Financial Strength Company Industry Sector S&P 500
Quick Ratio (MRQ) 4.46 8.75 3.14 1.30
Current Ratio (MRQ) 6.14 9.47 3.78 1.79
LT Debt to Equity (MRQ) 0.11 0.45 0.31 0.55
Total Debt to Equity (MRQ) 0.11 0.49 0.44 0.84
Interest Coverage (TTM) 24.23 -2.16 10.14 9.86
Profitability Ratios (%) Company Industry Sector S&P 500
Gross Margin (TTM) 64.92 64.17 68.53 50.29
Gross Margin - 5 Yr. Avg. 60.33 66.74 66.37 48.37
EBITD Margin (TTM) 40.50 7.77 23.01 23.09
EBITD - 5 Yr. Avg. 32.92 -4.80 20.38 21.25
Operating Margin (TTM) 35.93 0.23 18.12 17.94
Operating Margin - 5 Yr. Avg. 30.85 -13.38 12.86 16.94
Pre-Tax Margin (TTM) 75.21 2.70 19.01 17.88
Pre-Tax Margin - 5 Yr. Avg. 39.23 -11.80 13.22 16.75
Net Profit Margin (TTM) 47.92 -0.47 12.58 12.99
Net Profit Margin - 5 Yr. Avg. 25.53 -13.37 8.06 10.25
Management Effectiveness (%) Company Industry Sector S&P 500
Return On Assets (TTM) 22.07 -8.08 9.14 10.53
Return On Assets - 5 Yr. Avg. 15.67 -12.81 7.03 9.05
Return On Investment (TTM) 23.82 -7.58 13.95 13.97
Return On Investment - 5 Yr. Avg. 17.25 -10.06 12.73 14.22
Return On Equity (TTM) 29.89 -1.68 23.40 22.32
Return On Equity - 5 Yr. Avg. 19.39 -9.97 20.53 21.92
Efficiency Company Industry Sector S&P 500
Revenue/Employee (TTM) 374,003 346,527 340,275 615,548
Net Income/Employee (TTM) 179,213 74,729 65,197 103,543
Receivable Turnover (TTM) 5.10 8.79 7.00 8.62
Inventory Turnover (TTM) 2.15 5.04 3.83 9.58
Asset Turnover (TTM) 0.46 0.61 0.86 0.99
gruß
@ epicuraul:
Ich blick da durch vieles nicht durch:
p/e ist das KGV, richtig?
Die Zahlenreihen sind die vergangenen Jahre/Quartale?
Das Beta sagt mir nichts
Vielleicht kannst du auch einfach herausstellen, auf was es da wirklich ankommt.
Danke,
Mike
Ich blick da durch vieles nicht durch:
p/e ist das KGV, richtig?
Die Zahlenreihen sind die vergangenen Jahre/Quartale?
Das Beta sagt mir nichts
Vielleicht kannst du auch einfach herausstellen, auf was es da wirklich ankommt.
Danke,
Mike
Scheisse! Hier ist die dazugehörige Meldung:
RESEARCH ALERT- Watson Pharmaceuticals lowered
NEW YORK, Sept 13 (Reuters) - Donaldson Lufkin Jenrette said analyst Kenneth Kulju on Wednesday reduced his earnings projections on Watson Pharmaceuticals Inc. (NYSE:WPI - news) after the company warned of sharply lower-than-expected profits for the near-term related to its recent acquisition of Schein Pharmaceutical Inc.
-- Kulju said in a research note that he reduced third-quarter, fourth-quarter, and fiscal year 2000 earnings per share estimates to $0.04 from $0.47, to $0.38 from $0.54, and to $1.28 from $1.87 respectively.
-- Additional details were not immediately available.
-- Shares of Watson fell to $52 in pre-opening trading on Wednesday from a close of $64-1/8. The company cited higher costs and reduced product sales resulting from the Schein acquisition.
RESEARCH ALERT- Watson Pharmaceuticals lowered
NEW YORK, Sept 13 (Reuters) - Donaldson Lufkin Jenrette said analyst Kenneth Kulju on Wednesday reduced his earnings projections on Watson Pharmaceuticals Inc. (NYSE:WPI - news) after the company warned of sharply lower-than-expected profits for the near-term related to its recent acquisition of Schein Pharmaceutical Inc.
-- Kulju said in a research note that he reduced third-quarter, fourth-quarter, and fiscal year 2000 earnings per share estimates to $0.04 from $0.47, to $0.38 from $0.54, and to $1.28 from $1.87 respectively.
-- Additional details were not immediately available.
-- Shares of Watson fell to $52 in pre-opening trading on Wednesday from a close of $64-1/8. The company cited higher costs and reduced product sales resulting from the Schein acquisition.
WPI: Watson Pharmaceuticals Cautions on Earnings
By TSC Staff
9/13/00 7:52 AM ET
Watson Pharmaceuticals (WPI:NYSE - news) yesterday cautioned investors that it would report third-quarter cash earnings between 12 to 14 cents a share and GAAP earnings between 3 to 5 cents a share.
The 10-analyst estimate forecasts the company to post a 48-cent profit for the quarter. Watson blamed weak product sales associated with its purchase of Schein Pharmaceuticals, as well as pricing competition and operating expenses on the earnings shortfall.
By TSC Staff
9/13/00 7:52 AM ET
Watson Pharmaceuticals (WPI:NYSE - news) yesterday cautioned investors that it would report third-quarter cash earnings between 12 to 14 cents a share and GAAP earnings between 3 to 5 cents a share.
The 10-analyst estimate forecasts the company to post a 48-cent profit for the quarter. Watson blamed weak product sales associated with its purchase of Schein Pharmaceuticals, as well as pricing competition and operating expenses on the earnings shortfall.
Als ich heute in mein Depot schaute: 
Tut mir leid, aber ich lern das grade...
Mike
machs kurz und schmerzlos- stoppe aus!
falls ein gap aufgerissen wurde, kannst du auf die schließung warten, ist aber unwahrscheinlich- weil watson ist zu teuer geworden...
gruß
falls ein gap aufgerissen wurde, kannst du auf die schließung warten, ist aber unwahrscheinlich- weil watson ist zu teuer geworden...
gruß
Bin zwar nicht mehr drin, aber hier hab ich trotzdem noch was erfreuliches gefunden:
Watson Receives FDA Final Approval for Bisoprolol Fumarate And Hydrochlorothiazide ...
CORONA, Calif., Sep 25, 2000 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals,Inc. (NYSE: WPI) announced today that it has received final approval from the Food and Drug Administration (FDA) to manufacture and market its Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg. Bisoprolol Fumarate and Hydrochlorothiazide is the generic equivalent to Lederle Laboratories` Ziac(R), which is used for the treatment of hypertension.
Watson received final approval upon the expiration of Ziac`s pediatric exclusivity. Other companies also received final approval for this same generic product. Watson`s product will be manufactured in Cincinnati, Ohio by its contract manufacturer, Aventis. Shipments of Watson`s product have commenced.
Mike
Watson Receives FDA Final Approval for Bisoprolol Fumarate And Hydrochlorothiazide ...
CORONA, Calif., Sep 25, 2000 /PRNewswire via COMTEX/ -- Watson Pharmaceuticals,Inc. (NYSE: WPI) announced today that it has received final approval from the Food and Drug Administration (FDA) to manufacture and market its Bisoprolol Fumarate and Hydrochlorothiazide Tablets, 2.5 mg/6.25 mg, 5 mg/6.25 mg, and 10 mg/6.25 mg. Bisoprolol Fumarate and Hydrochlorothiazide is the generic equivalent to Lederle Laboratories` Ziac(R), which is used for the treatment of hypertension.
Watson received final approval upon the expiration of Ziac`s pediatric exclusivity. Other companies also received final approval for this same generic product. Watson`s product will be manufactured in Cincinnati, Ohio by its contract manufacturer, Aventis. Shipments of Watson`s product have commenced.
Mike
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 237 | ||
| 110 | ||
| 100 | ||
| 65 | ||
| 55 | ||
| 39 | ||
| 34 | ||
| 32 | ||
| 29 | ||
| 25 |
| Wertpapier | Beiträge | |
|---|---|---|
| 22 | ||
| 20 | ||
| 18 | ||
| 18 | ||
| 18 | ||
| 17 | ||
| 17 | ||
| 17 | ||
| 17 | ||
| 17 |
